Please assess the completion status of the following clinical trial:

Trial Title: Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ongoing participation in a Phase 2 \[LX1606.1-202-CS (NCT00853047), LX1606.1-203-CS (NCT01104415)\] or Phase 3 \[LX1606.1-301-CS (NCT01677910), LX1606.1-303-CS (NCT02063659)\] study~* Patients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of \<1% per year) during the study and for 12 weeks after the Follow-up visit.~* Ability and willingness to provide written informed consent~Exclusion Criteria:~* Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study~* Positive pregnancy test~* Presence of any clinically significant findings at entry for medical history, laboratory values, or physical examination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 250 mg Telotristat Etiprate (Type: EXPERIMENTAL): One telotristat etiprate (250 mg) tablet administered three times daily.
- 500 mg Telotristat Etiprate (Type: EXPERIMENTAL): Two telotristat etiprate (250 mg) tablets administered three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).